BioCentury | Apr 23, 2007
Clinical News

RP01: Phase II started

...a double-blind, placebo-controlled, dose-escalation, New Zealand Phase II trial of injectable RP01 in 42 patients. Resistentia Pharmaceuticals AB...
BioCentury | Nov 13, 2006
Company News

Biovitrum, Resistentia deal

...RES 08, the biopharmaceutical substance in Resistentia's RP01, for Phase III trials to treat allergy. Resistentia...
...February 2007 and to enter Phase III testing in 4Q09. Biovitrum AB (SSE:BVT), Stockholm, Sweden Resistentia Pharmaceuticals AB...
BioCentury | Sep 27, 2006
Financial News

Resistentia raises EUR 11 million

...by S.R. One. Existing investors HealthCap, Industrifonden, BankInvest and Innovationskapital also participated in the round. Resistentia's...
...IgE), is in Phase I testing to treat allergic asthma. S.R. One's Kent Gossett joined Resistentia's...
BioCentury | Sep 4, 2006
Clinical News

RP01: Interim Phase I data

...I trial showed that RP01 was well tolerated and induced anti-IgE antibodies in healthy volunteers. Resistentia Pharmaceuticals AB...
BioCentury | Feb 13, 2006
Clinical News

RP01: Phase I start

...Resistentia will begin in March a Swedish Phase I trial in healthy volunteers. Resistentia Pharmaceuticals AB , Uppsala...
BioCentury | Jan 16, 2001
Company News

BioInvent, Resistentia Pharmaceutical AB deal

...Resistentia to use in ongoing preclinical and clinical studies. BioInvent International AB , Lund, Sweden Resistentia...
BioCentury | Jan 9, 2001
Company News

BioInvent in Resistentia Anti-allergy Vaccine deal

...for Resistentia (Uppsala, Sweden) through its subsidiary BioInvent Production. BioInvent will produce the vaccine for Resistentia...
Items per page:
1 - 7 of 7
BioCentury | Apr 23, 2007
Clinical News

RP01: Phase II started

...a double-blind, placebo-controlled, dose-escalation, New Zealand Phase II trial of injectable RP01 in 42 patients. Resistentia Pharmaceuticals AB...
BioCentury | Nov 13, 2006
Company News

Biovitrum, Resistentia deal

...RES 08, the biopharmaceutical substance in Resistentia's RP01, for Phase III trials to treat allergy. Resistentia...
...February 2007 and to enter Phase III testing in 4Q09. Biovitrum AB (SSE:BVT), Stockholm, Sweden Resistentia Pharmaceuticals AB...
BioCentury | Sep 27, 2006
Financial News

Resistentia raises EUR 11 million

...by S.R. One. Existing investors HealthCap, Industrifonden, BankInvest and Innovationskapital also participated in the round. Resistentia's...
...IgE), is in Phase I testing to treat allergic asthma. S.R. One's Kent Gossett joined Resistentia's...
BioCentury | Sep 4, 2006
Clinical News

RP01: Interim Phase I data

...I trial showed that RP01 was well tolerated and induced anti-IgE antibodies in healthy volunteers. Resistentia Pharmaceuticals AB...
BioCentury | Feb 13, 2006
Clinical News

RP01: Phase I start

...Resistentia will begin in March a Swedish Phase I trial in healthy volunteers. Resistentia Pharmaceuticals AB , Uppsala...
BioCentury | Jan 16, 2001
Company News

BioInvent, Resistentia Pharmaceutical AB deal

...Resistentia to use in ongoing preclinical and clinical studies. BioInvent International AB , Lund, Sweden Resistentia...
BioCentury | Jan 9, 2001
Company News

BioInvent in Resistentia Anti-allergy Vaccine deal

...for Resistentia (Uppsala, Sweden) through its subsidiary BioInvent Production. BioInvent will produce the vaccine for Resistentia...
Items per page:
1 - 7 of 7